Family offices ramp up deal-making in June with bets on biotech
-
最新报道：Family offices increased deal activity in June, focusing on biotech and pharmaceutical investments, according to industry data. Several prominent family investment firms participated in late-stage funding rounds for emerging drug developers, signaling confidence in healthcare innovation. The trend reflects growing interest in life sciences as family offices seek long-term growth opportunities beyond traditional tech sectors. Notable transactions included a $200 million Series C round for a gene therapy startup and a $150 million investment in an AI-driven drug discovery platform. Experts attribute the surge to favorable regulatory developments and breakthrough scientific advancements in targeted therapies.
下一篇
The Inspiring Story Behind Jules Urbach and Render Network
- Jules Urbach, founder of Render Network, transitioned from a childhood passion for compute...
24小时热点
热点专题
407106